← Leaderboards
Sharon A Nachman
Johns Hopkins University
$214,342,272
Attributed
$214,342,272
Total exposure
39
Grants
30
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $24.9M · FY2005–25$25M$18.8M$12.5M$6.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$214,342,272 · 39
By mechanism
UM1$213,543,193 · 1
M01$799,079 · 38
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Philippa Musoke$9,335,883
- Sheree Renae Schwartz$6,682,424
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelUnited States National Institutes Of HealthChildClinical TrialsClinical ResearchAdolescentHiv InfectionsInfectionPharmaceutical PreparationsSafetyAnti-Retroviral AgentsVaccinesInfantDoseFundingPregnant WomenComputer Retrieval Of Information On Scientific Projects DatabaseResourcesGrantSiteInstitutionChildhoodSourceInternational Maternal Pediatric Adolescent Aids Clinical Trials
Grant awards (66)
IMPAACT Leadership Group$13,535,130
UM1 · FY2025 · AI · contact PI
IMPAACT Leadership Group$2,537,610
UM1 · FY2025 · AI · contact PI
IMPAACT Leadership Group$87,045
UM1 · FY2025 · AI · contact PI
IMPAACT Leadership Group$54,401
UM1 · FY2025 · AI · contact PI
IMPAACT Leadership Group$32,217
UM1 · FY2025 · AI · contact PI
IMPAACT Leadership Group$21,249
UM1 · FY2025 · AI · contact PI
IMPAACT Leadership Group$7,669
UM1 · FY2025 · AI · contact PI
IMPAACT Leadership Group$2,880
UM1 · FY2025 · AI · contact PI
IMPAACT Leadership Group$1
UM1 · FY2025 · AI · contact PI
IMPAACT Leadership Group$1
UM1 · FY2025 · AI · contact PI
IMPAACT Leadership Group$1
UM1 · FY2025 · AI · contact PI
IMPAACT Leadership Group$14,463,085
UM1 · FY2024 · AI · contact PI
IMPAACT Leadership Group$14,217,091
UM1 · FY2023 · AI · contact PI
IMPAACT Leadership Group$15,388,321
UM1 · FY2022 · AI · contact PI
IMPAACT Leadership Group$17,121,428
UM1 · FY2021 · AI · contact PI
LOC-IMPAACT Leadership Group$15,939,764
UM1 · FY2020 · AI · contact PI
LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the US$942,554
UM1 · FY2020 · AI · contact PI
LOC-IMPAACT Leadership Group$20,283,274
UM1 · FY2019 · AI · contact PI
LOC-IMPAACT Leadership Group$18,690,967
UM1 · FY2018 · AI · contact PI
LOC-IMPAACT Leadership Group$24,865,759
UM1 · FY2017 · AI · contact PI
LOC-IMPAACT Leadership Group$16,028,800
UM1 · FY2016 · AI · contact PI
LOC-IMPAACT Leadership Group$24,530,718
UM1 · FY2015 · AI · contact PI
LOC-IMPAACT Leadership Group$14,793,228
UM1 · FY2014 · AI · contact PI
CLINICAL TRIAL: NEURODEVELOPMENTAL / NEUROLOGICAL STUDY OF INFANTS/CHILDREN WITH$41,372
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE I/II MULTICENTER,OPEN LABEL,NONCOMPARITIVE STUDY OF HIV AF$19,244
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE I/II STUDY OF SAFETY AND IMMUNOGENICITY OF QUADRIVALENT ME$18,280
M01 · FY2009 · RR · contact PI
SURVEILLANCE MONITORING FOR ART TOXICITIES$17,319
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PSYCHIATRIC CO-MORBIDITY IN PERINATALLY HIV-INFECTED CHILDREN AN$8,659
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE II SAFETY AND IMMUNOGENICITY STUDY OF QUADRIVALENT HUMAN P$2,054
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: REGIMENS/TREATMENT SWITCHING STRATEGIES IN HIV CHILDREN ACTG390$1,925
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PEDIATRIC LATE OUTCOMES PROTOCOL ACTG 219C$43,038
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE I/II STUDY OF SAFETY AND IMMUNOGENICITY OF QUADRIVALENT ME$28,243
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PSYCHIATRIC CO-MORBIDITY IN PERINATALLY HIV-INFECTED CHILDREN AN$25,552
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: NEURODEVELOPMENTAL / NEUROLOGICAL STUDY OF INFANTS/CHILDREN WITH$18,830
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE II SAFETY AND IMMUNOGENICITY STUDY OF QUADRIVALENT HUMAN P$16,139
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: REGIMENS/TREATMENT SWITCHING STRATEGIES IN ANTIRETROVIRAL NAIVE$8,069
M01 · FY2008 · RR · contact PI
SURVEILLANCE MONITORING FOR ART TOXICITIES$6,727
M01 · FY2008 · RR · contact PI
PEDIATRIC LATE OUTCOMES PROTOCOL ACTG 219C$111,366
M01 · FY2007 · RR · contact PI
PSYCHIATRIC CO-MORBIDITY IN PERINATALLY HIV-INFECTED CHILDREN AND ADOLESCENTS$43,629
M01 · FY2007 · RR · contact PI
THE EFFECTS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)$11,480
M01 · FY2007 · RR · contact PI
REGIMENS/TREATMENT SWITCHING STRATEGIES IN ANTIRETROVIRAL NAIVE CHILDREN ACTG390$8,036
M01 · FY2007 · RR · contact PI
HAART REGIMENS IN HIV ADOLESCENTS PACT 1034$5,742
M01 · FY2007 · RR · contact PI
PHASE II SAFETY AND IMMUNOGENICITY STUDY OF QUADRIVALENT HUMAN PAPILLOMAVIRUS$5,742
M01 · FY2007 · RR · contact PI
A DUAL PI-BASED HAART REGIMEN VS A MULTI-NRTI ART REGIMEN, PACTG P1053$5,742
M01 · FY2007 · RR · contact PI
SLEEP AND HEALTH IN CHILDREN$5,230
M01 · FY2007 · RR · contact PI
IMMUNOLOGIC MEMORY FOLLOWING PNEUMOCOCCAL, HEP B, AND MEASLES VACCINATION P1061$4,042
M01 · FY2007 · RR · contact PI
PEDIATRIC LATE OUTCOMES PROTOCOL ACTG 219C$124,551
M01 · FY2006 · RR · contact PI
PACTG P-1045$17,952
M01 · FY2006 · RR · contact PI
PSYCHIATRIC CO-MORBIDITY IN PERINATALLY HIV-INFECTED CHILDREN AND ADOLESCENTS$16,831
M01 · FY2006 · RR · contact PI
A PHASE I/II RANDOMIZED TRIAL OF THE SAFETY AND IMMUNOGENICITY OF FLU MIST$13,465
M01 · FY2006 · RR · contact PI
REGIMENS/TREATMENT SWITCHING STRATEGIES IN ANTIRETROVIRAL NAIVE CHILDREN ACTG390$7,853
M01 · FY2006 · RR · contact PI
THE EFFECTS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)$6,733
M01 · FY2006 · RR · contact PI
PEDIATRIC LATE OUTCOMES PROTOCOL ACTG 219C$72,160
M01 · FY2005 · RR
A PHASE I/II RANDOMIZED TRIAL OF THE SAFETY AND IMMUNOGENICITY OF FLU MIST$19,996
M01 · FY2005 · RR
PACTG P-1045$10,432
M01 · FY2005 · RR
EFFECT OF ANTIRETROVIRAL THERAPY ON BODY COMPOSITION HIV-INFECTED CHILDREN AGTGP$6,085
M01 · FY2005 · RR
REGIMENS/TREATMENT SWITCHING STRATEGIES IN ANTIRETROVIRAL (HIV) NAIVE CHILDREN$6,085
M01 · FY2005 · RR
THE EFFECTS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)$3,477
M01 · FY2005 · RR
COGNITIVE, BEHAVIORAL AND PSYCHOSOCIAL CORRELATES OF MEDICATION ADHERENCE IN HIV$3,477
M01 · FY2005 · RR
Pediatric Late Outcomes Protocol ACTG 219c$29,113
M01 · FY2004 · RR
EFFECT OF ANTIRETROVIRAL THERAPY ON BODY COMPOSITION HIV-INFECTED CHILDREN AGTGP$3,528
M01 · FY2004 · RR
REGIMENS/TREATMENT SWITCHING STRATEGIES IN ANTIRETROVIRAL NAIVE CHILDREN ACTG390$881
M01 · FY2004 · RR
Trial of Pediatric AIDS Clinical Trials Group$0
M01 · FY2001 · RR
Antiretroviral Regimens--Combination of Protease Inhibitors$0
M01 · FY2001 · RR
Trial of Pediatric AIDS Clinical Trials Group$0
M01 · FY2000 · RR
Antiretroviral Regimens--Combination of Protease Inhibitors$0
M01 · FY2000 · RR